Antiviral Treatment and One-Year Follow-Up of Chronic Hepatitis B Patients in Bandung: An Observational Study

Authors

  • Eka Surya Nugraha Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung
  • Stefanie Hadi Supriami Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung
  • Nur Atik Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung
  • Nenny Agustanti Division of Gastroenterology and Hepatology, Department of Internal Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung
  • Yudi Wahyudi Division of Gastroenterology and Hepatology, Department of Internal Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung
  • Dolvy Girawan Division of Gastroenterology and Hepatology, Department of Internal Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung
  • M Begawan Bestari Division of Gastroenterology and Hepatology, Department of Internal Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung
  • Siti Aminah Abdurachman Division of Gastroenterology and Hepatology, Department of Internal Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung

DOI:

https://doi.org/10.24871/2322022117-122

Keywords:

Antiviral therapy, HBeAg, HBV-DNA, Hepatitis B Virus

Abstract

Background: Hepatitis B Virus (HBV) is a health problem that has chronically infected 257 million globally. Appropriate therapy is immensely needed to prevent disease progression to cirrhosis and hepatocellular carcinoma (HCC). Moreover, routine monitoring is required to assess the efficacy of the given treatment. This study aims to describe the treatment and its follow-up outcomes among chronic HBV patients after one year of therapy in Bandung.

Method: This was a cross-sectional descriptive study with a data sampling method obtained from assessing the medical records of treated chronic HBV outpatients at the Gastrohepatoenterology Clinic of Hasan Sadikin Hospital Bandung from 2018 to 2020. Laboratory findings before and after one year of therapy were further assessed.

Results: Out of 107 patients treated, the proportion of tenofovir was 72.90%, telbivudine 16.80%, lamivudine 8.40%, and interferon group 1.90%. There were 52.30% of patients who did follow-up visits after one year of therapy. The therapeutic outcome rate was evaluated among total patients with the criteria of decreasing AST (91.18%) and ALT levels (93.10%) levels, reduction of HBV-DNA values (100%), and HBeAg seroconversion (14.29%).

Conclusion: The most given therapy among chronic HBV outpatients was tenofovir. The follow-up rate of patients after one year of treatment was 52.30%. Overall, antiviral therapies produced decreases in liver laboratory parameters, HBV-DNA, and HBeAg.

 

Downloads

Published

2022-09-06

How to Cite

Nugraha, E. S., Supriami, S. H., Atik, N., Agustanti, N., Wahyudi, Y., Girawan, D., … Abdurachman, S. A. (2022). Antiviral Treatment and One-Year Follow-Up of Chronic Hepatitis B Patients in Bandung: An Observational Study. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 23(2), 117–122. https://doi.org/10.24871/2322022117-122

Issue

Vol. 23 No. 2 (2022): VOLUME 23, NUMBER 2, August 2022

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).